Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Foralumab

PharmaDeviceNews Foralumab

Representative image of multiple sclerosis research as Tiziana Life Sciences’ nasal foralumab reduces brain inflammation markers in a positive Phase 2a trial.

Pharma & Biotech

Nasal foralumab reduces brain inflammation marker in Phase 2a multiple sclerosis trial

by Soujanya Ravi
November 3, 2026
0 Comments

Tiziana Life Sciences' nasal foralumab meets Phase 2a multiple sclerosis endpoints. Explore brain inflammation, fatigue and safety findings.

Read More

Latest news and features

Mirum Pharmaceuticals prepares new brelovitug, volixibat and LIVMARLI data for AASLD 2026
Gilead’s weekly HIV pill has passed Phase 3, but can fewer doses deliver better treatment adherence?
HeartBeam 3D ECG achieves 81.8% specificity in 132-patient heart attack study, beating standard ECG on one measure
Nasal foralumab reduces brain inflammation marker in Phase 2a multiple sclerosis trial
Huntington’s disease treatment milestone: uniQure secures priority FDA review for one-time gene therapy
Urologic Design raises $1.2m to advance patented male incontinence device towards first human trial
Egnite and Pathway Labs launch FDA-cleared ECG AI pilot at Stamford Health to improve structural heart disease detection
Abbott’s SonicForce recorded just 0.3% lesion failure, but can it challenge Shockwave in coronary calcium treatment?
Impella registries show better survival than CHIP-BCIS3, but can Johnson & Johnson explain the conflicting evidence?
Reflow Medical reports zero major cardiac events at one year in nine-patient Spur Elute study
GE HealthCare unveils Allia Celeo AI-guided interventional system with European CE marking
Altruist Biologics secures NMPA priority review for localised production of multinational client’s biologic

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

Kim Jong Un’s teenage daughter emerges as likely North Korea successor as dynasty enters new phase
Halloween celebrations turn deadly across America as shootings leave at least 13 dead and 92 injured
Tower Semiconductor profit more than doubles as AI connectivity demand lifts quarterly revenue to $526m
Alstom faces €1.5bn cash drain as train manufacturing delays force major restructuring
Florida Learjet crash kills nine as investigators examine icing and catastrophic 27,000-foot plunge

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.